II. Epidemiology
- Bipolar Incidence: 1% of adults (United States)
- Gender predisposition: Men and women equally affected
- Age of onset: Early adulthood to mid-40s
- Affective disorder Family History confers risk
- One parent with affective disorder: 27%
- Two parents with affective disorder: 50-75%
- Mean age onset
- Bipolar I: Age 18 years
- Bipolar II: Age 22 years
- Llifetime Incidence
- Bipolar I: 0.6%
- Bipolar I: 0.4%
III. Risk Factors
- Family History of affective disorder or Bipolar Disorder (see epidemiology as above)
- Stressful life events
- Acute stress often triggers initial episode
- Childhood Trauma and adverse events
- Family member Suicide
- Disrupted sleep cycle
IV. Pathophysiology
- Related to noradrenergic system (Norepinephrine)
V. Types
- Bipolar I Disorder
- Mania Diagnosis criteria met
- Psychosis may be present
- Major Depression may be present
- Bipolar II Disorder
- Recurrent Major Depression
- Hypomanic episodes that do not meet criteria for Mania Diagnosis
- Cyclothymic Disorder (Cyclothymia)
- Depressive symptoms that do not meet criteria for Major Depression
- Hypomanic episodes that do not meet criteria for Mania Diagnosis
- Bipolar II Diagnosis not met
- Occurs for over 2 years, and with only two months or less symptom free
- Bipolar Disorder with Mixed Features
- Concurrent features of Hypomania/mania and depression
- Substance-Induced Mania
- See Substance-Induced Psychotic Disorder
- Examples: Methamphetamine, Cocaine, Alcohol, Corticosteroids
- Miscellaneous
- Bipolar Disorder not otherwise specified (does not meet criteria for other Bipolar Disorders)
- Bipolar Disorder unspecified (unconfirmed diagnosis for acute presentation)
VI. History
- Recurrent Major Depression
- Typically onset by age 13 years
- May present as Seasonal Affective Disorder (seasonal variability to depression episodes)
- Failed response to at least three Antidepressants
- Atypical Depression
- Hypersomnia
- Pathologic guilt
- Labile Mood or significant irritability
- Attempted Suicide
- Manic symptoms
- Mania or Hypomania episodes
- Periods of intense goal oriented activity
- Decreased need for sleep
- Racing thoughts interfere with sleep
- Psychosis
- Agitation or mania caused by Antidepressant, Corticosteroid or other medication
- Episodic hypersexuality
- Impulsive or irrational behavior
- Comorbid mental health disorders (up to 75% have 3 concurrent mental health disorders)
- See associated conditions as below
- Substance Use Disorder (Drug Abuse or Alcohol Abuse)
- Anxiety Disorder
- Attention Deficit Disorder
-
Family History
- Bipolar Disorder Family History
- Multiple relatives with Major Depression, Anxiety Disorder, Panic Disorder or Attention Deficit Disorder
- Multiple relatives with Suicidality, incarceration, Drug Abuse or Alcohol Abuse
- Impaired social functioning
- Multiple divorces
- Legal or financial problems
- Recurrent job loss
- Triggers
VII. Symptoms: Adults
- Maintains several days with reduced sleep and without feeling tired
- Frequent mood swings (or mood lability) or periods of intense goal orientation
- Racing thoughts interfere with sleep onset
-
Sleep disruptions trigger mania or Hypomania
- Seasonal changes in spring and fall
- Jet Lag on time zone changes
- Shift work or child care
- Associated symptoms
- Irritability
- Impulsivity
- Irrationality
VIII. Symptoms: Children
- Present with irritability, sadness and Insomnia (euphoria is typically absent)
IX. Symptoms: Miscellaneous Features Present in Some Bipolar Patients
- Anxious Distress
- Feeling restless, Excessive Worry, loss of control
- Associated with increased Suicidality risk
- Atypical features
- Depression related sleeping more and eating more
- Catatonic State
- Melancholia
- Psychotic features
- Rapid Cycling (Bipolar 1 Disorder)
X. Exam
- Background
- Thorough evaluation provides baseline before medications and evaluates for secondary causes and complications
- Obtain full Vital Signs
- Full physical exam
- See Mental Status Exam
- See Psychosis Exam
- Neurologic Exam including gait
XI. Differential Diagnosis
XII. Associated Conditions
- Anxiety Disorder
- Impulse Control
- Attention Deficit Disorder
- Substance Use Disorder
- Cardiovascular Disease
- Bipolar disease patients have twice the risk of cardiovascular disease than general population
- Screen for Cardiovascular Risk Factors
XIII. Diagnosis
- Specific Bipolar Disorder diagnosis (see Types above) rely on diagnostic criteria for Major Depression and mania/Hypomania
- See Major Depression Diagnosis
- See Mania Diagnosis
- See Hypomania Diagnosis
XIV. Grading: Severity
- Mild
- Diagnosis criteria met
- Mild functional Impairment
- Moderate
- Severe
- Severe distress and functional Impairment
XV. Labs: Consider for evaluation of secondary causes
- Highest yield tests
- Thyroid Function Tests (Thyroid Stimulating Hormone)
- Urine Drug Screen
- Urinalysis
- Older patients to evaluate for Urinary Tract Infection
-
Sexually Transmitted Diseases
- Syphilis Serology (e.g. RPR)
- HIV Test
- Hepatitis C
- Uncommon to rare causes
- Heavy Metal levels
- Serum Ammonia level
XVI. Labs: Consider for baseline labs prior to starting medications
- Complete Blood Count
- Chemistry panel with Renal Function tests
- Liver Function Tests
-
Serum Prolactin
- Antipsychotics may increase Prolactin levels
- Consider in patients with Amenorrhea, Galactorrhea, Gynecomastia
- Urine Pregnancy Test
-
Electrocardiogram (for baseline QT Interval)
- Many neuropsychiatric medications risk QT Prolongation
- Also provides baseline EKG due to Bipolar Disorder associated cardiovascular disease risk
- Cardiovascular Disease Risk Screening
XVII. Diagnostics: Consider if suggested by history or examination
- Head MRI
- Electroencephalogram (EEG)
XVIII. Management: General
- Continue mood stabilizers indefinately due to high relapse rate
- Consult psychiatry for comanagement
- Discuss Teratogenicity of medications with women of child bearing age
- Reliable Contraception is critical
- Do not use Antidepressants as monotherapy for mania, mixed disorder or Bipolar Disorder
- High risk of triggering manic episode
- Avoid medications that are more likely to trigger or exacerbate mania
- Avoid Trazodone
- Avoid Tricyclic Antidepressants
- Avoid SNRIs (e.g. Venlafaxine or Duloxetine)
- Patient should keep their own of medications, adverse effects and effectiveness
- Employ behavioral management as a first line therapy to reduce psychosocial stress
- Cognitive Behavioral Therapy
- Caregiver Support
- Regular Exercise
- Coping Strategy education
- Well Balanced Nutrition
- Intensive psychotherapy for exacerbations
- Manage comorbidity
- Patients and their family should be aware of early warning signs of relapse and emergency features
- Sleep disturbance
- Agitation
- Increased goal oriented activity
- Disrupted routine
- Suicidality
- Homicidality
- Clinicians should be alert for Extrapyramidal Side Effects (and modify therapy to reduce adverse effects)
- Perform Abnormal Involuntary Movement Scale (AIMS) at least every 6 months while on Antipsychotic Medications
- Akathisia
- Motor restlessness (differentiate from worsening mania, anxiety)
- May increase Suicidality
- Parkinsonism
- Dystonia
- Dyskinesia
- Tardive Dyskinesia
- Particular caution in elderly, cardiovascular disease risk, HIV Infection, neurologic disorders
- Consider medication dose reduction at every visit
- Adverse effects (esp. Extrapyramidal Side Effects) should prompt dose reduction (or medication change)
- Especially consider lower dose in children, older adults, underweight and with chronic disease
- Dose increases are needed with exacerbations
XIX. Management: Acute
- Acute Mania
- Hospitalize due to high risk of self harm or Suicidality
- Therapy goals
- Adequate sleep
- Reduce psychotic symptoms
- Medication protocol
- Start mood stabilizer (see below)
- Start adjunctive therapy (see below)
- Indicated while mood stabilizer (esp. Lithium) reaches steady state over days
- Atypical Antipsychotic (e.g. Olanzapine, Quetiaprine) or Haloperidol
- Benzodiazepines (e.g. Lorazepam)
- Acute Hypomania
- Medication management is similar to acute mania
- Observe for major depressive episode immediately following acute Hypomania episode
- Assess for functional capacity
- Decision making
- Compliance with treatment
- Acute Major Depression
- Hospitalize for Suicidality or Homicidal Thoughts
- Psychotherapy
- First-line therapies (combination of mood stabilizer with Atypical Antipsychotic)
- Primary mood stabilizers are both effective for Major Depression
- Atypical Antipsychotics effective for Major Depression
- Quetiapine or Seroquel (preferred)
- Risk of weight gain, Glucose Intolerance, and Extrapyramidal Side Effects
- Olanzapine (Zyprexa)
- Cariprazine (Vraylar)
- Lurasidone (Latuda)
- Quetiapine or Seroquel (preferred)
- Second-line therapies
- Add only to first line agents if effect is incomplete
- Do not use standard Antidepressants without mood stabilizers
- These agents do not increase efficacy over mood stabilizers alone
- Avoid Tricyclic Antidepressants, Trazodone, or Venlafaxine which can trigger manic episodes
- Selective Serotonin Reuptake Inhibitors
- Bupropion (Wellbutrin)
- Anticonvulsants effective for Major Depression
- Lamotrigine or Lamictal (preferred)
- Requires 6 weeks to titrate to level (due to Steven's Johnson Syndrome risk)
- Carbamazepine or Tegretol
- Topiramate
- Lamotrigine or Lamictal (preferred)
- Add only to first line agents if effect is incomplete
- Acute Mixed Features (combined features of Major Depression and mania/Hypomania)
- Avoid Lithium in mixed features or rapid cycling presentation (ineffective)
- Avoid monotherapy with Antidepressant for mixed features presentation
- Atypical Antidepressants are preferred in acute mixed feature presentations
- Refractory Cases
- Consider switching mood stabilizer
- Consider combining 2-3 mood stabilizers
- Consider Electroconvulsive Therapy
- Older patients
- Refractory to medications
- Catatonia
- Acute Psychosis with Suicidality
XX. Management: Mood Stabilizer Selection
- Mood stabilizer options
- First-line agents
- Lithium (preferred)
- Valproate
- Loading dose in acute mania: 15-20 mg/kg
- Starting dose without load: 500 to 750 mg/day in divided dosing
- Titrate every 2-3 days as tolerated to serum Valproic Acid level of 50 to 125 mcg/ml
- Target dose: 200 to 1600 mg daily
- Alternative mood stabilizers (consider for specific indications)
- Carbamazepine (Tegretol)
- Starting dose 200 mg twice daily
- Therapeutic range for biopolar: 4-12 mcg/ml
- Available as long acting agent (Equetro)
- Oxcarbazepine
- Consider instead of Carbamazepine
- Similar efficacy with fewer adverse effects
- Lamotrigine (Lamictal)
- Starting dose 25 mg daily
- Effective as mood stabilizer and Antidepressant
- No blood monitoring needed
- Rash develops in 10% of patients (Risk of Steven's Johnson)
- Requires slow titration over at least 6 weeks to effective dose
- Titrate Lamotrigine slowly (2 week increments)
- Do not exceed 100 mg when combined with Valproate
- Compared with Lithium
- Similar efficacy in treating depressive symptoms and reducing the need for additional psychotropics
- Less effective than Litium in recurrent mania prevention (but more effective than Placebo)
- Fewer adverse effects than Lithium
- Hashimoto (2021) Cochrane Database Syst Rev (9):CD013575 +PMID: 34523118 [PubMed]
- Carbamazepine (Tegretol)
- First-line agents
- Specific agent indications
- Classic mania or Hypomania (Euphoric mood)
- Mixed episode or rapid cycling
- Valproate (preferred) or
- Carbamazepine
- Combinations in refractory cases
- Lithium with Lamotrigine OR Valproate
- Valproate with Lithium OR Lamotrigine
XXI. Management: Adjunctive Medications
- Adjunctive medications: Benzodiazepine
- Examples: Lorazepam, Clonazepam
- Indications for Benzodiazepine
- Mania or Hypomania with Insomnia or Agitation
- Psychosis refractory to Antipsychotic
- Alternatives
- Consider Gabapentin for anxiety
- Adjunctive medications: Antipsychotics
- Precautions
- Monitor for Extrapyramidal Side Effects (e.g. Tardive Dyskinesia)
- Atypical Antipsychotic agents have specific lab monitoring guidelines
- Antipsychotic indications
- Psychosis
- Consider Electroconvulsive Therapy
- Mania with Insomnia or Agitation
- Despite Benzodiazepine
- Acute mania episode
- Antipsychotic use may increase Lithium or Valproate efficacy
- Psychosis
- Agents (low doses are often effective in mania)
- Risperidone (Risperdal) 2-4 mg per day
- Olanzapine (Zyprexa) 10-15 mg per day
- Lurasidone (Latuda) 20 mg orally daily (may advance gradually to 60 mg daily)
- Quetiapine 400-800 mg per day
- Mood stabilizers have improved efficacy when used with Quetiapine
- Quetiapine may be used as an alternative to Lithium for monotherapy
- Effective in mania, depression and mixed disorder and prevents future episodes
- Yatham (2009) Bipolar Disord 11(3):225-55 [PubMed]
- (2024) Am Fam Physician 109(6): 585-7
- Avoid Antipsychotics with lower efficacy in Bipolar Disorder
- Avoid Aripiprazole (Abilify)
- Avoid Ziprasidone (Geodon)
- Precautions
- Adjunctive medications: Antidepressants
- See Acute Depression Management above
- First-line agents
- Second-line agents (used only in combination with mood stabilizers)
- Selective Seotonin Reuptake Inhibitors (SSRIs) or Bupropion
- Risk of precipitating mania (do not use as montherapy)
- Avoid Tricyclic Antidepressants, Trazodone, or Venlafaxine which can trigger manic episodes
- Avoid Paroxetine (Paxil) as it is less effective in Bipolar Disorder
- May taper off 6-8 weeks after full bipolar remission (restart as needed)
- Selective Seotonin Reuptake Inhibitors (SSRIs) or Bupropion
- Other adjunctive measures (insufficient evidence)
XXII. Prognosis
- Relapse Rate
- One year: 25% with treatment (40% without treatment)
- Five years: 70% (regardless of treatment)
-
Suicide Attempt: 33% lifetime risk (half of those within the last year)
- Higher risk with anxious stress
- Completed Suicide in 6-7%
- Within 6 weeks of hospital discharge in 26%
- Schaffer (2015) Aust N Z J Psychiatry 49(11): 1006-20 [PubMed]
XXIII. References
- (2015) Presc Lett 22(1): 4
- (1997) Am Fam Physician 55(4):1447-9 [PubMed]
- Docherty (1996) J Clin Psychiat 57(suppl 12A):1-89 [PubMed]
- Marzani (2021) Am Fam Physician 103(4): 227-39 [PubMed]
- Manning (2010) J Clin Psychiatry 12(suppl 1): 17-22 [PubMed]
- McIntyre (2004) Can Fam Physician 50:388-94 [PubMed]
- Price (2012) Am Fam Physician 85(5): 483-93 [PubMed]
- Werder (1995) Am Fam Physician 51(5):1126-36 [PubMed]